Advertisement Carna Biosciences signs distribution agreement with SUBC - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Carna Biosciences signs distribution agreement with SUBC

Carna Biosciences, a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs and providing drug discovery services to pharmaceutical companies, has signed a distribution agreement with Shanghai Universal Biotech Company, a Chinese distributor of biological reagents and experimental installations.

Under the terms of this agreement, Shanghai Universal Biotech Company (SUBC) will become the exclusive distributor of Carna’s protein kinases within China. The agreement with SUBC makes these products readily available to Chinese researchers via SUBC’s strong distribution channels, said Carna.

The agreement between Carna and SUBC, with its offices in the cities of Shanghai and Beijing, is anticipated to lead to significantly increased sales opportunities for Carna and further establish its reputation as a global provider of protein kinases, according to Carna.